TickerFacts.

Q32 Bio Inc. (QTTB): Revenue

Annual figures by period end, from SEC filings.

$53.74M
Year ended 2025-12-31
2018-12-31: $3.68M2023-12-31: -$6.65M2024-12-31: $02025-12-31: $53.74M$53.74M
2018-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$53.74Mn/a2026-03-10, From 2025-01-01
2024-12-31$0n/m2026-03-10, From 2024-01-01
2023-12-31-$6.65Mn/a2025-03-11, From 2023-01-01
No annual figure between 2018-12-31 and 2023-12-31.
2018-12-31$3.68Mn/a2019-03-12, From 2018-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Q32 Bio Inc. (QTTB)2025-12-31$53.74Mn/a
Agios Pharmaceuticals, Inc. (AGIO)2025-12-31$54.03M+48.0%
Nektar Therapeutics (NKTR)2025-12-31$55.23M-43.9%
Ocular Therapeutix, Inc (OCUL)2025-12-31$51.95M-18.5%
Aytu Biopharma, Inc (AYTU)2026-06-30$57.57M-13.3%
Lexicon Pharmaceuticals, Inc. (LXRX)2025-12-31$49.80M+60.2%
Gossamer Bio, Inc. (GOSS)2025-12-31$48.47M-57.7%
Journey Medical Corp (DERM)2025-12-31$61.24M+11.1%
Tango Therapeutics, Inc. (TNGX)2025-12-31$62.38M+48.3%

Compare QTTB, AGIO, NKTR, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗